Castle Biosciences Unveils New Data on Melanoma Risk Assessment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy CSTL?
Source: PRnewswire
- Clinical Data Presentation: Castle Biosciences will present data from a study of 1,817 early-stage melanoma patients at the 2026 EADO Congress, demonstrating that the DecisionDx-Melanoma test provides independent, personalized prognostic information beyond AJCC staging, thereby aiding physicians in more precise risk management.
- Risk Identification Capability: The test identifies recurrence risks in patients with thin tumors, revealing that their recurrence rates are comparable to those of higher-stage patients, which underscores the need for precise clinical management decisions in early-stage disease.
- Survival Rate Analysis: At the ACMS meeting, Castle will share an analysis based on SEER registry data showing that DecisionDx-Melanoma can identify molecularly high-risk T1a and T1b patients with significantly lower 5-year melanoma-specific survival, highlighting the importance of managing low-risk populations effectively.
- Personalized Management Decisions: By integrating molecular insights with clinicopathologic features, DecisionDx-Melanoma provides personalized assessments of sentinel lymph node positivity and recurrence risk, enabling clinicians to make more informed management decisions early on, consistent with National Comprehensive Cancer Network guideline risk thresholds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.160
Low
41.00
Averages
47.20
High
52.00
Current: 25.160
Low
41.00
Averages
47.20
High
52.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Castle Biosciences Unveils New Data on Melanoma Risk Assessment
- Clinical Data Presentation: Castle Biosciences will present data from a study of 1,817 early-stage melanoma patients at the 2026 EADO Congress, demonstrating that the DecisionDx-Melanoma test provides independent, personalized prognostic information beyond AJCC staging, thereby aiding physicians in more precise risk management.
- Risk Identification Capability: The test identifies recurrence risks in patients with thin tumors, revealing that their recurrence rates are comparable to those of higher-stage patients, which underscores the need for precise clinical management decisions in early-stage disease.
- Survival Rate Analysis: At the ACMS meeting, Castle will share an analysis based on SEER registry data showing that DecisionDx-Melanoma can identify molecularly high-risk T1a and T1b patients with significantly lower 5-year melanoma-specific survival, highlighting the importance of managing low-risk populations effectively.
- Personalized Management Decisions: By integrating molecular insights with clinicopathologic features, DecisionDx-Melanoma provides personalized assessments of sentinel lymph node positivity and recurrence risk, enabling clinicians to make more informed management decisions early on, consistent with National Comprehensive Cancer Network guideline risk thresholds.
See More
Castle Biosciences to Release Q1 2026 Financial Results on May 6
- Earnings Release Schedule: Castle Biosciences will announce its Q1 2026 financial results after market close on May 6, 2026, demonstrating the company's commitment to financial transparency, which is expected to positively impact investor confidence.
- Webcast Discussion: Management will host a live webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, aimed at enhancing investor engagement and providing deeper financial insights.
- Focus on Innovative Testing: Castle Biosciences specializes in innovative tests for dermatologic and gastroenterological diseases, striving to improve patient management and outcomes through personalized clinical solutions, reflecting the company's strategic positioning in the healthcare sector.
- Brand and Market Promotion: The company actively promotes its brand and products through its website and social media platforms, enhancing public awareness of its innovative tests, with the goal of increasing market share and attracting more patients and clinicians' attention.
See More
Castle Biosciences Wins 2026 USA TODAY Top Workplaces Award for Fifth Year
- Consecutive Award Achievement: Castle Biosciences has won the 2026 USA TODAY Top Workplaces Award for the fifth consecutive year, reflecting the company's ongoing commitment to employee care and culture building, which enhances its reputation and attractiveness in the healthcare industry.
- Employee Feedback Driven: The award is based on employee feedback collected through a third-party survey, indicating the company's high performance in employee experience, which further boosts its credibility among job seekers and customers.
- Cultural Investment Commitment: CEO Derek Maetzold emphasized that building a people-first culture is a continuous investment process, ensuring that employees feel valued and supported, thereby increasing employee loyalty and job satisfaction.
- Industry Impact: Winning this award not only recognizes the company's culture but also establishes a positive corporate image for Castle Biosciences in a competitive market, attracting more top talent and driving business growth.
See More
Castle Biosciences Wins USA TODAY Top Workplaces Award for Fifth Year
- Consecutive Awards: Castle Biosciences has won the 2026 USA TODAY Top Workplaces Award for the fifth consecutive year, highlighting the company's exceptional performance in employee satisfaction and corporate culture, thereby reinforcing its leadership position in the healthcare sector.
- Employee Feedback Driven: The award is based on anonymous employee feedback collected through Energage, indicating the company's success in establishing a people-first culture, which enhances employee belonging and loyalty, ultimately improving overall work efficiency.
- Leadership Commitment: CEO Derek Maetzold emphasized that continuous investment in employee culture is central to the company's strategy, ensuring that employees feel valued and supported, which not only boosts morale but also creates a favorable environment for attracting and retaining talent.
- Market Competitive Advantage: Winning this award not only enhances Castle Biosciences' brand credibility but also provides a trusted badge for job seekers and customers, signaling the company's commitment to valuing its people and increasing its appeal in a competitive market.
See More
Castle Biosciences Presents New Melanoma Survival Data at AAD 2026
- Significant Survival Improvement: Castle Biosciences' DecisionDx-Melanoma test significantly stratifies five-year melanoma-specific survival within AJCC stages, with a 96.7% survival rate for low-risk T1 patients compared to 70.0% for high-risk patients, indicating the test's effectiveness in identifying high-risk patients and guiding clinical decisions.
- Personalized Management Decisions: By incorporating DecisionDx-Melanoma into routine risk assessment, physicians gain biological insights that enable more confident escalation of care for higher-risk patients while avoiding unnecessary interventions for lower-risk patients, thereby optimizing patient management.
- Data Supporting Clinical Application: The study, based on data from 1,868 patients across 22 SEER sites, demonstrates the test's ability to identify high-risk and low-risk patients that AJCC staging alone cannot accurately predict, supporting more precise risk-aligned management decisions.
- Future Research Directions: Castle Biosciences will present detailed findings at the 2026 American Academy of Dermatology Annual Meeting, further advancing personalized treatment and management strategies for melanoma, which is expected to have a profound impact on clinical practice.
See More
Castle Biosciences Presents New Melanoma Survival Data at AAD 2026
- Significant Survival Improvement: Castle Biosciences' DecisionDx-Melanoma test significantly stratifies five-year melanoma-specific survival within AJCC stages, with low-risk T1 patients showing a 96.7% survival rate compared to 70.0% for high-risk patients, indicating the test's effectiveness in identifying high-risk individuals and guiding clinical decisions.
- Personalized Management Decisions: By incorporating DecisionDx-Melanoma into routine risk assessments, physicians gain biological insights that enable them to confidently escalate care for higher-risk patients while avoiding unnecessary interventions for those at lower risk, thereby optimizing patient management.
- Data Supporting Clinical Application: The study is based on data from 1,868 patients across 22 SEER sites, demonstrating that the test provides actionable risk stratification within AJCC subgroups, highlighting the limitations of traditional staging in accurately assessing patient risk.
- Future Research Directions: Castle Biosciences will present detailed findings at the 2026 American Academy of Dermatology Annual Meeting and plans to publish in the Journal of the American Academy of Dermatology, further advancing personalized treatment approaches for melanoma.
See More
Castle Biosciences Unveils New Data on Melanoma Risk Assessment
- Clinical Data Presentation: Castle Biosciences will present data from a study of 1,817 early-stage melanoma patients at the 2026 EADO Congress, demonstrating that the DecisionDx-Melanoma test provides independent, personalized prognostic information beyond AJCC staging, thereby aiding physicians in more precise risk management.
- Risk Identification Capability: The test identifies recurrence risks in patients with thin tumors, revealing that their recurrence rates are comparable to those of higher-stage patients, which underscores the need for precise clinical management decisions in early-stage disease.
- Survival Rate Analysis: At the ACMS meeting, Castle will share an analysis based on SEER registry data showing that DecisionDx-Melanoma can identify molecularly high-risk T1a and T1b patients with significantly lower 5-year melanoma-specific survival, highlighting the importance of managing low-risk populations effectively.
- Personalized Management Decisions: By integrating molecular insights with clinicopathologic features, DecisionDx-Melanoma provides personalized assessments of sentinel lymph node positivity and recurrence risk, enabling clinicians to make more informed management decisions early on, consistent with National Comprehensive Cancer Network guideline risk thresholds.
See More
Castle Biosciences to Release Q1 2026 Financial Results on May 6
- Earnings Release Schedule: Castle Biosciences will announce its Q1 2026 financial results after market close on May 6, 2026, demonstrating the company's commitment to financial transparency, which is expected to positively impact investor confidence.
- Webcast Discussion: Management will host a live webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, aimed at enhancing investor engagement and providing deeper financial insights.
- Focus on Innovative Testing: Castle Biosciences specializes in innovative tests for dermatologic and gastroenterological diseases, striving to improve patient management and outcomes through personalized clinical solutions, reflecting the company's strategic positioning in the healthcare sector.
- Brand and Market Promotion: The company actively promotes its brand and products through its website and social media platforms, enhancing public awareness of its innovative tests, with the goal of increasing market share and attracting more patients and clinicians' attention.
See More
Castle Biosciences Wins 2026 USA TODAY Top Workplaces Award for Fifth Year
- Consecutive Award Achievement: Castle Biosciences has won the 2026 USA TODAY Top Workplaces Award for the fifth consecutive year, reflecting the company's ongoing commitment to employee care and culture building, which enhances its reputation and attractiveness in the healthcare industry.
- Employee Feedback Driven: The award is based on employee feedback collected through a third-party survey, indicating the company's high performance in employee experience, which further boosts its credibility among job seekers and customers.
- Cultural Investment Commitment: CEO Derek Maetzold emphasized that building a people-first culture is a continuous investment process, ensuring that employees feel valued and supported, thereby increasing employee loyalty and job satisfaction.
- Industry Impact: Winning this award not only recognizes the company's culture but also establishes a positive corporate image for Castle Biosciences in a competitive market, attracting more top talent and driving business growth.
See More
Castle Biosciences Wins USA TODAY Top Workplaces Award for Fifth Year
- Consecutive Awards: Castle Biosciences has won the 2026 USA TODAY Top Workplaces Award for the fifth consecutive year, highlighting the company's exceptional performance in employee satisfaction and corporate culture, thereby reinforcing its leadership position in the healthcare sector.
- Employee Feedback Driven: The award is based on anonymous employee feedback collected through Energage, indicating the company's success in establishing a people-first culture, which enhances employee belonging and loyalty, ultimately improving overall work efficiency.
- Leadership Commitment: CEO Derek Maetzold emphasized that continuous investment in employee culture is central to the company's strategy, ensuring that employees feel valued and supported, which not only boosts morale but also creates a favorable environment for attracting and retaining talent.
- Market Competitive Advantage: Winning this award not only enhances Castle Biosciences' brand credibility but also provides a trusted badge for job seekers and customers, signaling the company's commitment to valuing its people and increasing its appeal in a competitive market.
See More
Castle Biosciences Presents New Melanoma Survival Data at AAD 2026
- Significant Survival Improvement: Castle Biosciences' DecisionDx-Melanoma test significantly stratifies five-year melanoma-specific survival within AJCC stages, with a 96.7% survival rate for low-risk T1 patients compared to 70.0% for high-risk patients, indicating the test's effectiveness in identifying high-risk patients and guiding clinical decisions.
- Personalized Management Decisions: By incorporating DecisionDx-Melanoma into routine risk assessment, physicians gain biological insights that enable more confident escalation of care for higher-risk patients while avoiding unnecessary interventions for lower-risk patients, thereby optimizing patient management.
- Data Supporting Clinical Application: The study, based on data from 1,868 patients across 22 SEER sites, demonstrates the test's ability to identify high-risk and low-risk patients that AJCC staging alone cannot accurately predict, supporting more precise risk-aligned management decisions.
- Future Research Directions: Castle Biosciences will present detailed findings at the 2026 American Academy of Dermatology Annual Meeting, further advancing personalized treatment and management strategies for melanoma, which is expected to have a profound impact on clinical practice.
See More
Castle Biosciences Presents New Melanoma Survival Data at AAD 2026
- Significant Survival Improvement: Castle Biosciences' DecisionDx-Melanoma test significantly stratifies five-year melanoma-specific survival within AJCC stages, with low-risk T1 patients showing a 96.7% survival rate compared to 70.0% for high-risk patients, indicating the test's effectiveness in identifying high-risk individuals and guiding clinical decisions.
- Personalized Management Decisions: By incorporating DecisionDx-Melanoma into routine risk assessments, physicians gain biological insights that enable them to confidently escalate care for higher-risk patients while avoiding unnecessary interventions for those at lower risk, thereby optimizing patient management.
- Data Supporting Clinical Application: The study is based on data from 1,868 patients across 22 SEER sites, demonstrating that the test provides actionable risk stratification within AJCC subgroups, highlighting the limitations of traditional staging in accurately assessing patient risk.
- Future Research Directions: Castle Biosciences will present detailed findings at the 2026 American Academy of Dermatology Annual Meeting and plans to publish in the Journal of the American Academy of Dermatology, further advancing personalized treatment approaches for melanoma.
See More
